P654: Controversies in the management of anti-TNF therapy in Crohn's disease patients. A Delphi consensusECCO’23 CopenhagenYear: 2023
Authors: Gonzalez Lama, Y.(1)*;Ricart, E.(2);Carpio, D.(3);Bastida, G.(4);Ceballos, D.(5);Ginard, D.(6);Marín-Jimenéz, I.(7);Menchén, L.(8);Muñoz, F.(9);
(1)Hospital Universitario Puerta de Hierro- Majadahonda, Gastroenterology Department, Madrid, Spain;(2)Hospital Clínic de Barcelona, Inflammatory Bowel Disease Unit, Barcelona, Spain;(3)Complexo Hospitalario Universitario de Pontevedra, Gastroenterology Department, Pontevedra, Spain;(4)La Fe University and Polytechnic Hospital, Gastroenterology Department, Valencia, Spain;(5)Hospital Universitario Doctor Negrin, Gastroenterology Department, Las Palmas de Gran Canaria, Spain;(6)Hospital Universitario Son Espases, Gastroenterology Department, Palma de Mallorca, Spain;(7)Hospital Universitario Gregorio Marañón, Gastroenterology Department- Departamento de Medicina- Facultad de Medicina- Universidad Complutense de Madrid, Madrid, Spain;(8)Hospital General Universitario-Insitituto de Investigación Sanitaria Gregorio Marañón, Gastroenterology Department- Departamento de Medicina- Facultad de Medicina- Universidad Complutense de Madrid, Madrid, Spain;(9)Hospital Universitario de Salamanca, Gastroenterology Department, Salamanca, Spain;
P655: MadCAM1 Negativity of Lamina Propria Endothelial Cells is Associated with Non-Response to Vedolizumab in Inflammatory Bowel Disease PatientsECCO’23 CopenhagenYear: 2023
Authors: Zelinkova, Z.(1)*;Podmanicky, D.(2);Berakova, K.(3);Kadleckova, B.(1);
(1)Nemocnica Bory - Penta Hospitals, Department of Gastroenterology, Bratislava, Slovakia;(2)Nemocnica Bory - Penta Hospitals, Department of Surgery, Bratislava, Slovakia;(3)Martinske Biopticke Centrum, Department of Pathology, Zilina, Slovakia;
P656: Superior treatment persistence with ustekinumab in biologic-experienced luminal Crohn's disease: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyECCO’23 CopenhagenYear: 2023
Authors: Chetwood, J.(1,2)*;Ko, Y.(1);Pudipeddi, A.(1,2);Kariyawasam, V.(3);Paramsothy, S.(1,2);Leong, R.(1,2);
(1)Concord Repatriation General Hospital, Gastroenterology, Sydney, Australia;(2)University of Sydney, Medicine and Health, Sydney, Australia;(3)Blacktown hospital, Gastroenterology, Sydney, Australia;
P657: Current landscape of the real-world utilization of Interleukins 22, 23 and Interleukin 22 binding protein as biomarkers for Inflammatory Bowel Disease (IBD): A targeted literature reviewECCO’23 CopenhagenYear: 2023
Authors: Dolin, P.(1)*;Evans, K.(2);Castañeda, J.(3);Udayachalerm, S.(2);Cabrera, C.(4);
(1)Astrazeneca, Medical & Payer Evidecne, Cambridge, United Kingdom;(2)Evidera, Real-World Evidence, Waltham- MA, United States;(3)Evidera, Real-World Evidence, Paris, France;(4)Astrazeneca, Real-World Science & Analytics, Mölndal, Sweden;
P658: Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect ComparisonECCO’23 CopenhagenYear: 2023
Authors: Reinisch, W.(1)*;Tran, J.(2,3);Patel, K.(4);Borruel, N.(5);Melmed, G.Y.(6);Wegrzyn, L.(3);Levy, G.(3);Ilo, D.(3);Sanchez Gonzalez, Y.(3);Panaccione, R.(7);
(1)Medical University of Vienna, n/a, Wien, Austria;(2)University of Washington, The Comparative Health Outcomes- Policy- and Economics Institute, Seattle, United States;(3)AbbVie Inc., n/a, Chicago, United States;(4)St. George's University Hospital, NHS Foundation Trust, London, United Kingdom;(5)Hospital Vall d'Hebron, Crohn's and Colitis Attention Unit- Digestive System Service, Barcelona, Spain;(6)Cedars-Sinai Medical Center, n/a, Los Angeles, United States;(7)University of Calgary, Department of Gastroenterology and Hepatology, Calgary, Canada;
P659: Continuing or stopping 5-aminosalicylate in patients with Inflammatory Bowel Disease under anti-TNF therapy: A nationwide population-based studyECCO’23 CopenhagenYear: 2023
Authors: Seo, J.(1)*;Kim, S.(2);Song, S.(1);Shin, S.H.(1);Park, S.(1);Hong, S.W.(1);Hwang, S.W.(1,3);Park, S.H.(1,3);Yang, D.H.(1);Byeon, J.S.(1);Myung, S.J.(1);Yang, S.K.(1,3);Kim, Y.J.(2);Ye, B.D.(1,3);
(1)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology, Seoul, Korea- Republic Of;(2)Asan Medical Center- University of Ulsan College of Medicine, Clinical Epidemiology and Biostatistics, Seoul, Korea- Republic Of;(3)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P660: Body composition and health-related quality of life in adult Crohn's Disease during clinical remission: The INTICO2 cohort studyECCO’23 CopenhagenYear: 2023
Authors: McDonnell, M.(1,2)*;Sartain , S.(1);Westoby , C.(3);Katarachia, V.(3);Davis, C.(4);Cummings, F.(1);Wootton, S.(2);
(1)University Hospital Southampton, Gastroenterology, Southampton, United Kingdom;(2)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;(3)University Hospital Southampton, Department of Nutrition and Dietetics, Southampton, United Kingdom;(4)University Hospital Southampton, Clinical Informatics Research Unit, Southampton, United Kingdom;
P661: Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn's disease: data from the ADVANCE and MOTIVATE studiesECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Dotan, I.(2,3);Ferrante, M.(4);Danese, S.(5,6);Bossuyt, P.(7);Kligys, K.(8);Neimark, E.(8);Zambrano, J.(8);Liao, X.(8);D'Haens, G.(9);
(1)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(2)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(3)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(4)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)IRCCS San Raffaele Hospital, Department of Gastroenterology and Endoscopy, Milan, Italy;(6)Vita-Salute San Raffaele University, Gastroenterology, Milan, Italy;(7)Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium;(8)AbbVie Inc., Research and Development, North Chicago, United States;(9)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands Antilles;
P662: Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Lin, S.(1,2)*;Chanchlani, N.(1,2);Smith, R.(1,2);Roberts, C.(1,2);Nice, R.(3);McDonald, T.J.(3);Hamilton, B.(2);Bewshea, C.(2);Kennedy, N.A.(1,2);Goodhand, J.R.(1,2);Ahmad, T.(1,2);
(1)Royal Devon University Healthcare NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)Royal Devon University Healthcare NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;PANTS consortium
P663: Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC CohortECCO’23 CopenhagenYear: 2023
Authors: An, Y.K.(1)*;Lindsay, N.(2);Allan, N.(2);Khoo, E.(1);Fernandes, R.(1);Amiss, A.(2);Pham, H.(2);Wong, K.F.(2);Ooi, S.Y.(3);Thin, L.(4);Lightowler, D.(4);Connor, S.J.(5);Williams, A.J.(5);De Cruz, P.(6);Li Wai Suen, C.(6);Kariyawasam, V.(7);Mitrev, N.(7);Ghaly, S.(8);Andrews, J.M.(9);Christensen, B.(10);Sparrow, M.P.(11);White, L.S.(12);Bryant, R.V.(13);Ding, N.(14);Leong, R.(15);Van Langenberg, D.(16);Seltenreich, H.(17);Subramaniam, K.(18);Radford-Smith, G.(3);Begun, J.(19);
(1)Mater Hospital Brisbane, Department of Gastroenterology, Brisbane, Australia;(2)Mater Research Institute, IBD Research Group, Brisbane, Australia;(3)Royal Brisbane and Women's Hospital, Department of Gastroenterology, Brisbane, Australia;(4)Fiona Stanley Hospital, Department of Gastroenterology, Perth, Australia;(5)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(6)Austin Hospital, Department of Gastroenterology, Melbourne, Australia;(7)Blacktown Hospital, Department of Gastroenterology, Sydney, Australia;(8)St Vincent's Hospital Sydney, Department of Gastroenterology, Sydney, Australia;(9)Royal Adelaide Hospital, Department of Gastroenterology, Adelaide, Australia;(10)Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(11)Alfred Hospital, Department of Gastroenterology, Melbourne, Australia;(12)Sunshine Coast University Hospital, Department of Gastroenterology, Brisbane, Australia;(13)The Queen Elizabeth Hospital, Department of Gastroenterology, Adelaide, Australia;(14)St Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(15)Concord Hospital, Department of Gastroenterology, Sydney, Australia;(16)Eastern Health, Department of Gastroenterology, Melbourne, Australia;(17)Costal Digestive Health, Clinical Research Unit, Brisbane, Australia;(18)Canberra Hospital, Department of Gastroenterology, Canberra, Australia;(19)Mater Hospital Brisbane, Department of Gastroenterolgy, Brisbane, Australia;Australia New Zealand IBD Consortium (ANZIBDC)
P664: Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBDECCO’23 CopenhagenYear: 2023
Authors: Vieujean, S.(1)*;Lindsay, J.O.(2,3);Rubin, D.(4);D'Amico, F.(5,6);Ahuja, V.(7);Silverberg, M.S.(8);Sood, A.(9);Yamamoto-Furusho, J.K.(10);Nagahori, M.(11);Watanabe, M.(12);Koutroubakis, I.E.(13);Foteinogiannopoulou, K.(13);Walsh, A.(14);Outtier, A.(15);Abreu, M.T.(16);Dubinsky, M.(17);Siegel, C.(18);Louis, E.(1);Dotan, I.(19);Reinisch, W.(20);Danese, S.(5);Peyrin-Biroulet, L.(21);
(1)CHU Liège- Sart Tilman, Department of Gastroenterology, Liège, Belgium;(2)Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom;(3)The Royal London Hospital- Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(4)University of Chicago, Medicine Inflammatory Bowel Disease Center, Chicago- IL, United States;(5)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Endoscopy, Milan, Italy;(6)Humanitas University- Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy;(7)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(8)Toronto Immune and Digestive Health Institute, Toronto Immune and Digestive Health Institute, Toronto, Canada;(9)Dayanand Medical College and Hospital, Department of Gastroenterology, Ludhiāna- Punjab, India;(10)Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Inflammatory Bowel Disease Clinic- Department of Gastroenterology, Tlalpa, Mexico;(11)Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan;(12)Tokyo Medical and Dental University, Advanced Research Institute, Tokyo, Japan;(13)University Hospital of Heraklion, Department of Gastroenterology, Heraklion- Crete, Greece;(14)Oxford University Hospitals NHS Foundation Trust and NIHR Biomedical Research Centre, Translational Gastroenterology Unit- John Radcliffe Hospital, Oxford, United Kingdom;(15)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)University of Miami Miller School of Medicine, Division of Gastroenterology- Department of Medicine, Miami- FL, United States;(17)Icahn School of Medicine, Division of Pediatric Gastroenterology and Nutrition, Mount Sinai- New York, United States;(18)Dartmouth-Hitchcock Medical Center, Inflammatory Bowel Disease Center- Section of Gastroenterology and Hepatology, Lebanon, United States;(19)Rabin Medical Center- Sackler Faculty of Medicine, Division of Gastroenterology, Tel Aviv, Israel;(20)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;(21)Nancy University Hospital- University of Lorraine, Department of Gastroenterology NGERE INSERM U1256, Vandœuvre-lès-Nancy, France;
P665: Social Media Listening to better Understand the Lived Experience of Individuals With Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Auriat, O.(1);Lucats, L.(1)*;Badalamenti, S.(2);Kruger, A.(2);Wiekowski, M.(2);Glotfelty, L.(2);Van Hoogstraten, H.(3);Coulouvrat, C.(4);
(1)Sanofi Recherche & Développement - 1 avenue Pierre Brossolette, Sanofi Recherche & Développement - 1 avenue Pierre Brossolette, Chilly-Mazarin, France;(2)Sanofi Research and Development- 55 Corporate Drive- Bridgewater New Jersey 08807- United States of America, Sanofi Research and Development- 55 Corporate Drive- Bridgewater New Jersey 08807- United States of America, Bridgewater, United States;(3)Sanofi Global Medical Affairs- 55 Corporate Drive- Bridgewater New Jersey 08807- United States of America, Sanofi Global Medical Affairs- 55 Corporate Drive- Bridgewater New Jersey 08807- United States of America, Bridgewater, United States;(4)Sanofi Research and Development- 1 avenue Pierre Brossolette- CHILLY-MAZARIN 91385- France, Sanofi Research and Development- 1 avenue Pierre Brossolette- CHILLY-MAZARIN 91385- France, Chilly-Mazarin, France;
P666: Effect of anastomotic configuration on Crohn's Disease recurrence after primary ileocolic resection. A comparative monocentric study of end-to-end versus side-to-side anastomosis.ECCO’23 CopenhagenYear: 2023
Authors: Bislenghi, G.(1);Vancoillie, P.J.(1)*;Fieuws, S.(2);Verstockt, B.(3);Sabino, J.(4);Wolthuis, A.(1);D'Hoore, A.(1);
(1)University Hospitals Leuven, Abdominal Surgery, Leuven, Belgium;(2)Catholic Univeristy Leuven and University of Hasselt, Interuniversity Institute for Biostatistics and statistical Bioinformatics, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatolog, Leuven, Belgium;
P667: USTEkinumAb Double intravenous loading induction therapY at week 0,4 in patients with Crohn's Disease– results from STEADY studyECCO’23 CopenhagenYear: 2023
Authors: Chin, A.(1)*;Jeffrey, A.(1);Teh, W.L.(1);Menon, S.(1);So, K.(1);Venugopal, K.(1);Picardo, S.(1);
(1)Royal Perth Hospital, Department of Gastroenterology, Perth, Australia;
P668: Differential efficacy of biologic agents for Inflammatory Bowel Disease Unclassified and comparison with Ulcerative Colitis: a propensity score analysis of 4054 patients from the UK IBD BioResourceECCO’23 CopenhagenYear: 2023
Authors: Kapizioni, C.(1)*;Desoki, R.(1,2);Balendran, K.(1);Lam, D.(1);Shawky, R.(3);Pele, L.(3);Parkes, M.(1);Raine, T.(1);
(1)Cambridge University Hospital, Gastroenterology Department, Cambridge, United Kingdom;(2)Alexandria University, Genetics Department, Alexandria, Egypt;(3)Cambridge University Hospital, IBD BioResource, Cambridge, United Kingdom;
P669: Improving Crohn's disease stricture dilation outcome: Effect of repeated dilation, needle knife stricturotomy, and ongoing active inflammationECCO’23 CopenhagenYear: 2023
Authors: Schulberg, J.D.(1,2)*;Hamilton, A.L.(1,2);Wright, E.K.(1,2);Holt, B.(1,2);Sutherland, T.(2,3);Ross, A.L.(1);Vogrin, S.(2);Kamm, M.A.(1,2);
(1)St. Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(2)The University of Melbourne, Department of Medicine, Melbourne, Australia;(3)St. Vincent's Hospital, Department of Medical Imaging, Melbourne, Australia;
P670: “What Matters To You?” – How do patient views compare with a patient experience framework and UK national standards of care?ECCO’23 CopenhagenYear: 2023
Authors: Sheldon, E.(1)*;Roman, S.(2);Randall, K.(2);Rachel, H.(3);Winsor, G.(4);Wakeman, R.(5);Lobo, A.(2);
(1)The University of Sheffield, School of Health and Related Research, Sheffield, British Virgin Islands;(2)Sheffield Teaching Hospitals NHS Foundation Trust, Gastroenterology, Sheffield, United Kingdom;(3)The University of Sheffield, School of Health and Related Research, Sheffield, United Kingdom;(4)Crohn's & Colitis UK, Research & Quality Improvement, Hatfield, United Kingdom;(5)Crohn's & Colitis UK, Services- Advocacy & Evidence, Hatfield, United Kingdom;on behalf of the AWARE-IBD Study Group
P671: Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extensionECCO’23 CopenhagenYear: 2023
Authors: Turner, D.(1)*;Rosh, J.R.(2);Cohen, S.A.(3);Griffiths, A.(4);Hyams, J.S.(5);Kierkuś, J.(6);Adedokun, O.J.(7);Strauss, R.(8);Kim, L.(9); Volger, S.(10);
(1)Shaare Zedek Medical Center- The Hebrew University of Jerusalem, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)Goryeb Children's Hospital/Atlantic Health, Pediatric Gastroenterology, Morristown- NJ, United States;(3)GI Care for Kids, Pediatric Gastroenterology, Atlanta- GA, United States;(4)The Hospital for Sick Children- University of Toronto, Pediatric Gastroenterology, Toronto- ON, Canada;(5)Connecticut Children's Medical Center, Pediatric Gastroenterology, Hartford- CT, United States;(6)The Children's Memorial Health Institute, Department of Gastroenterology- Hepatology- Feeding Disorders- and Paediatrics, Warsaw, Poland;(7)Janssen Research and Development- LLC, Clinical Pharmacology, Spring House- PA, United States;(8)Janssen Research and Development- LLC, Immunology, Horsham- PA, United States;(9)Janssen Research and Development- LLC, Biostatistics, Spring House- PA, United States;(10)Janssen Research and Development- LLC, Immunology, Spring House- PA, United States;UniStar Investigators
P672: Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodiesECCO’23 CopenhagenYear: 2023
Authors: AnjieMD, S.(1)*;Hanžel, J.(2);Gecse, K.B.(1);D'Haens, G.R.(1);Brandse, J.F.(3);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)University Medical Center Ljubljana, Department of Gastroenterology and Hepatology, Ljubjana, Slovenia;(3)Rijnstate, Department of Gastroenterology and Hepatology, Arnhem, The Netherlands;
P673: The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort studyECCO’23 CopenhagenYear: 2023
Authors: Jagt, J.(1,2)*;Galestin, S.(3);Benninga, M.(1);de Boer, N.(4);de Meij, T.(1);
(1)Amsterdam UMC- location University of Amsterdam, Department of Pediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Amsterdam UMC- Vrije Universiteit Amsterdam, Pediatric Gastroenterology- Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands;(3)Amsterdam UMC- location University of Amsterdam, Faculty of Medicine, Amsterdam, The Netherlands;(4)Amsterdam UMC- Vrije Universiteit Amsterdam, Department of Gastroenterology and Hepatology- Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam, The Netherlands;
